Outset Medical, Inc.

OM Healthcare Medical Devices

Outset Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $119.5 million, up 5.09% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 6.73%, free cash flow fell 90.5% and total debt rose 4.20%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

3.94 0.14 −3.43%
Market cap
$76.6M
P/E
0.0×
Fwd P/E
−1.1×
Dividend yield
—
F-score
6/9
Altman Z
−5.37
Beneish M
−3.25
Dividend safety
n/a
Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— — — — 5 3 3 5 6
P/E ratio
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
— — — 5.79 12.44 2.01 (3.92) (5.41) (5.37)
P/S ratio
— 0.00 0.00 18.63 20.49 10.40 2.14 0.51 0.47
Altman Z″-Score (non-manufacturers)
— — (14.26) 3.67 3.17 (2.18) (8.02) (10.47) (9.87)
P/FCF ratio
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Beneish M-Score
— — — — (3.18) (3.50) (3.25) (3.00) (3.25)
P/Operating CF
— (18.32) (18.32) (36.00) (64.34) (34.77) (11.44) (3.50) (5.93)
P/B ratio
— 0.00 0.00 2.83 5.62 4.88 2.28 2.15 0.44
Price to Tangible BV
— 0.00 0.00 2.83 5.62 4.88 2.28 2.15 0.44
EV/Sales
— 0.00 0.00 12.94 17.48 8.75 1.59 0.86 (0.13)
EV/EBITDA
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.24
EV/Operating CF
— (2.14) (2.14) (6.52) (13.77) (6.93) (1.58) (0.84) 0.33
EV/FCF
— (2.00) (2.00) (5.98) (13.45) (6.55) (1.54) (0.83) 0.32
Quick Ratio
— 14.09 2.97 8.76 7.06 6.07 4.27 4.28 5.24
Current Ratio
— 14.46 3.20 9.43 7.93 7.19 5.26 5.69 6.67
Net Debt/EBITDA
— 2.46 0.59 2.50 2.51 1.23 0.43 (0.34) 1.13
Debt/Assets
0.00% 0.00% 32.89% 7.35% 6.42% 24.08% 41.46% 71.57% 36.39%
Debt/Equity
— 0.00 0.78 0.09 0.08 0.39 1.06 7.36 0.76
Asset Turnover
— 0.00 0.34 0.20 0.24 0.27 0.37 0.39 0.44
Operating CF/Net income
— 0.64 0.82 1.25 0.99 0.89 0.76 0.91 0.57
Capex/Depreciation
— (6.09) (6.57) (2.83) (0.44) (1.48) 6.15 (0.90) (0.38)
Interest Coverage
— (10.04) (16.52) (40.63) (76.10) (45.15) (13.39) (4.75) (4.78)
ROE
— 22.14% 25.89% 364.06% (37.55%) (52.56%) (93.69%) (170.97%) (106.20%)
ROA
— 0.00% (193.43%) (32.23%) (30.42%) (37.74%) (48.41%) (43.41%) (30.23%)
ROIC
— 0.00% 0.00% (169.11%) (126.76%) (183.56%) (213.60%) (108.17%) (76.86%)
Return on Tangible Assets
— (52.07%) (136.45%) (24.47%) (35.56%) (48.27%) (69.35%) (57.91%) (37.47%)
Average Days of Receivables
— 197.87 94.75 47.28 91.07 88.80 92.33 114.36 86.55
Research and Development Expense of Revenue
— 1,141.80% 154.71% 57.78% 35.81% 42.34% 43.96% 33.77% 17.77%
Selling, General and Administrative Expense of Revenue
— 873.54% 193.51% 151.36% 98.81% 112.67% 108.50% 99.87% 77.19%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
— 39.26% 5.86% 42.93% 17.00% 23.58% 29.63% 25.82% 13.07%
Graham Net Nets
— 0.46 0.46 0.29 0.15 0.18 0.36 0.16 2.01
Graham Number
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
— (31.41%) (31.41%) (23.70%) (6.25%) (13.69%) (62.02%) (223.31%) (183.02%)
Free Cash Flow Yield
— (34.92%) (34.92%) (11.62%) (6.34%) (12.84%) (48.22%) (203.29%) (83.51%)
Revenue per Share
— 41.47 263.60 45.77 33.74 35.92 39.45 32.83 7.85
Operating CF per Share
— (959.55) (1,228.88) (90.75) (42.84) (45.37) (39.75) (33.58) (3.05)
Capex per Share
— (36.49) (57.57) (8.32) (1.02) (2.59) (1.04) (0.26) (0.05)
Free Cash Flow per Share
— (996.03) (1,286.45) (99.07) (43.86) (47.96) (40.79) (33.85) (3.10)
Cash per Share
— 2,950.04 1,225.14 288.58 111.64 89.50 61.52 45.82 11.11
Shareholders Equity per Share
— 0.00 651.38 301.17 123.02 76.58 37.18 7.74 8.35
Interest Debt per Share
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
— 0.00 651.38 301.17 123.02 76.58 37.18 7.74 8.35
Free Cash Flow
— (48.21) (73.58) (108.09) (133.37) (154.05) (134.81) (117.21) (47.12)
Working Capital
— 137.43 54.74 309.22 358.11 321.70 235.90 212.84 213.25
Capital Expenditures
— (1.77) (3.29) (9.08) (3.11) (8.32) (3.44) (0.91) (0.80)
Net Current Asset Value
— 147.65 28.54 270.69 320.42 219.52 100.30 9.25 113.34
EV/EBIT
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.23
Capex to Sales
— 0.88 0.22 0.18 0.03 0.07 0.03 0.01 0.01
Price to Operating Income
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
— 0.10 0.06 0.21 0.55 0.35 (0.04) 0.12 0.45
Cash ROIC
— (28.08%) (53.95%) (16.06%) (17.94%) (24.46%) (29.54%) (30.61%) (12.02%)
Accounts Receivable Turnover
— 0.80 6.03 9.62 6.40 4.30 4.27 3.31 3.74
Accounts Payable Turnover
— 1.95 7.89 12.71 28.31 82.45 31.53 15.51 32.94
Inventory Turnover
— 2.13 8.63 5.48 3.30 2.15 2.01 1.38 1.36
Average Days of Payables
— 151.58 55.06 28.68 6.77 2.26 20.98 18.76 2.78
Days of Inventory on Hand
— 135.81 51.02 106.56 150.56 192.62 177.20 288.54 238.96
Average Receivables
— 2.50 2.50 5.19 16.03 26.84 30.53 34.30 31.97
Average Payables
— 4.17 4.17 4.95 3.36 1.18 3.22 4.84 2.21
Average Inventory
— 3.81 3.81 11.49 28.78 45.33 50.35 54.30 53.50
Average Assets
— 0.00 44.18 246.10 433.65 431.79 356.96 294.80 270.15
Average Common Equity
— (330.07) (330.07) (21.79) 351.35 310.04 184.44 74.85 76.89

Fold the line items

Columns are period end dates